Publications by authors named "Sami Al-Rawi"
Article Synopsis
- * The study included nearly 7,000 patients, revealing that the median heart volume increased over time, and the median mean heart dose (MHD) remained low, indicating effective radiation management.
- * Findings suggest that, despite an increase in heart volume, the average heart dose during treatment was minimal, demonstrating the feasibility of large-scale audits with automated tools for better patient care.
Development and comprehensive evaluation of a national DBCG consensus-based auto-segmentation model for lymph node levels in breast cancer radiotherapy.
Radiother Oncol
December 2024
Article Synopsis
- This study focused on training a deep learning model to help doctors identify important areas in breast cancer patients that need treatment.
- It used expert opinions from radiotherapy centers in Denmark to create high-quality data for training the model.
- The results showed that the model's performance was very similar to what experienced doctors would achieve, which means it could be used safely in real medical situations.
Background And Purpose: Guideline adherence in radiotherapy is crucial for maintaining treatment quality and consistency, particularly in non-trial patient settings where most treatments occur. The study aimed to assess the impact of guideline changes on treatment planning practices and compare manual registry data accuracy with treatment planning data.
Materials And Methods: This study utilised the DBCG RT Nation cohort, a collection of breast cancer radiotherapy data in Denmark, to evaluate adherence to guidelines from 2008 to 2016.
Background: The purpose was to investigate the treatment flow of patients with HER2-positive metastatic breast cancer (mBC), progression-free survival (PFS) and overall survival (OS) across treatment lines and adherence to guidelines (defined as trastuzumab, pertuzumab and chemotherapy first line, where 85% received vinorelbine as backbone and T-DM1 second line). Furthermore, we identified clinical markers to predict the risk of developing brain metastases.
Material And Methods: Patients with HER2-positive mBC, diagnosed between 01.
Background: Dual blockade with trastuzumab and pertuzumab combined with neoadjuvant chemotherapy (NACT) has been increasingly used for HER2-positive tumours >2 cm and/or with positive axillary lymph nodes in order to evaluate pathologic response and obtain better surgical management. SB3 is a registered biosimilar trastuzumab approved following a phase III trial demonstrating similar efficacy in the neoadjuvant setting as trastuzumab. However, the study was done without pertuzumab.
View Article and Find Full Text PDF